Search results
Results from the WOW.Com Content Network
[28] [29] IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles. [ 30 ] [ 31 ] The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS. [ 9 ]
IMS stood for Intercontinental Medical Statistics. It was the largest vendor of U.S. physician prescribing data. [2] [3] [4] IMS Health was founded in 1954 by Bill Frohlich and David Dubow with Arthur Sackler having a hidden ownership stake. [5] In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green ...
Syngenta rejecteded another unsolicited offer from Monsanto, worth $45 billion, with management saying it undervalued the company and a merger would carry significant risks. Monsanto offered to acquire the company at a price of 449 Swiss francs per Syngenta share, with approximately 45% of the price paid in cash. [29] [30] 19 2014
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
Quintiles Announces Pricing of Initial Public Offering Stock Expected to Begin Trading on NYSE May 9th RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles today announced the pricing of its ...
From November 2008 to March 2010, if you bought shares in companies when Dennis D. Dammerman joined the board, and sold them when he left, you would have a -36.5 percent return on your investment, compared to a 30.9 percent return from the S&P 500.
Average CEO Pay is calculated using the last year a director sat on the board of each company. Stock returns do not include dividends. All directors refers to people who sat on the board of at least one Fortune 100 company between 2008 and 2012. The Pay Pals project relies on financial research conducted by the Center for Economic Policy and ...
Gillings is the founder and former chairman of Quintiles, a contract research organization. [6] In 1994, he took Quintiles public through an IPO . [ 6 ] Quintiles is the "largest global provider of clinical trials and commercial marketing services to the pharmaceutical and biotechnology industry". [ 5 ]